Abstract
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the commonest skin malignancies and if diagnosed early have a good prognosis. Conversely, metastatic disease is rarely associated with a very poor prognosis. Locally advanced BCC is also uncommon and may not be amendable to surgery, radiation therapy or photodynamic therapy. The activation of the hedgehog pathway occurs in 90% of BCCs and inhibition of this pathway with well tolerated oral agents has resulted in an important therapeutic option in some patients with locally advanced or metastatic BCC. In contrast, metastatic SCC tends to behave biologically more aggressively and cisplatin based chemotherapy has very limited efficacy.
Keywords: Chemotherapy, targeted therapy, basal cell carcinoma, squamous cell carcinoma, nonmelanoma.
Current Cancer Therapy Reviews
Title:Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer
Volume: 12 Issue: 3
Author(s): Vamsee Torri
Affiliation:
Keywords: Chemotherapy, targeted therapy, basal cell carcinoma, squamous cell carcinoma, nonmelanoma.
Abstract: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the commonest skin malignancies and if diagnosed early have a good prognosis. Conversely, metastatic disease is rarely associated with a very poor prognosis. Locally advanced BCC is also uncommon and may not be amendable to surgery, radiation therapy or photodynamic therapy. The activation of the hedgehog pathway occurs in 90% of BCCs and inhibition of this pathway with well tolerated oral agents has resulted in an important therapeutic option in some patients with locally advanced or metastatic BCC. In contrast, metastatic SCC tends to behave biologically more aggressively and cisplatin based chemotherapy has very limited efficacy.
Export Options
About this article
Cite this article as:
Torri Vamsee, Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer, Current Cancer Therapy Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573394713666161229124633
DOI https://dx.doi.org/10.2174/1573394713666161229124633 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes
Current Drug Targets CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Current Drug Targets Autophagy and Crohns Disease: At the Crossroads of Infection, Inflammation, Immunity, and Cancer
Current Molecular Medicine Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics
Current Medicinal Chemistry Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging Ototoxicity: Mechanisms of Cochlear Impairment and its Prevention
Current Medicinal Chemistry The Molecular Basis of Susceptibility to Infection in Liver Cirrhosis
Current Medicinal Chemistry Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma
Current Drug Targets Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism Targeting Toll-Like Receptor Signaling Pathways for Design of Novel Immune Therapeutics
Current Drug Discovery Technologies Evolution and Pathogenesis of Oncoviruses Associated with Head and Neck Cancer: History and Current Concepts
Recent Patents on Biomarkers One Hundred Faces of Cyclopamine
Current Pharmaceutical Design Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Mechanisms Underlying Chemopreventive Effects of Flavonoids via Multiple Signaling Nodes within Nrf2-ARE and AhR-XRE Gene Regulatory Networks
Current Chemical Biology